NASDAQ: PSTI; DAX: PJT: PLTR has filed a shelf prospectus with the US SEC to raise up to $150M in shares, preferred shares, and warrants. Read more…
The US FDA designated PSTI’s PLX cells orphan status for the treatment of thromboangiitis obliterans (Buerger’s disease). Read more…
PSTI entered into an exclusive license agreement with United Therapeutics Corporation Read more…
Q1/11 net loss of $2.61M or $0.07 per share Read more…
PSTI completed 3 and 6 month clinical follow-up data Read more…
Expands Testing of PLX Cells for the Treatment of Radiation Exposure Read more…
With a number of Critical Limb Ischemia (CLI) trials being initiated, the real race at this point will be to enroll sites and patients for these trials. Read more…
PSTI and New York University (NYU) Medical Center formed a partnership Read more…
Research offers promising cell treatment for the Muscle Injury. Read more…
PSTI (TASE:PLTR) closed its $38M public offering of 11,000,000 units, Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.